Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol. 2010 Feb; 7(2):71-2.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.